Evolution of extravascular implantable defibrillator technologies

Anna Pfenniger, Bradley Paul Knight*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

The implantable cardioverter-defibrillator (ICD) has been successfully treating patients with lethal ventricular arrhythmias for decades. The main acute and chronic complications of this therapy modality are related to the use of a transvenous lead. An entirely extravascular ICD concept was developed over the last 20 years, with emergence of the subcutaneous ICD (S-ICD). This device was approved for clinical use seven years ago, and accumulating real-life experience confirms its safety and efficacy. The main limitations related to this system include the lack of pacing capabilities for bradycardia, tachycardia or resynchronization therapy, a large size, and relatively high energy requirements for effective defibrillation. This review article summarizes current knowledge and potential future developments of the extravascular ICD technologies.

Original languageEnglish (US)
Pages (from-to)249-255
Number of pages7
JournalProgress in Cardiovascular Diseases
Volume62
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Implantable Defibrillators
Technology
Bradycardia
Tachycardia
Cardiac Arrhythmias
Safety
Equipment and Supplies
Therapeutics

Keywords

  • Modular cardiac rhythm management system
  • S-ICD
  • Subcutaneous implantable cardioverter-defibrillator
  • Substernal lead
  • Ventricular arrhythmias

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{52fccdab1b3e440aa80a73ac1a877712,
title = "Evolution of extravascular implantable defibrillator technologies",
abstract = "The implantable cardioverter-defibrillator (ICD) has been successfully treating patients with lethal ventricular arrhythmias for decades. The main acute and chronic complications of this therapy modality are related to the use of a transvenous lead. An entirely extravascular ICD concept was developed over the last 20 years, with emergence of the subcutaneous ICD (S-ICD). This device was approved for clinical use seven years ago, and accumulating real-life experience confirms its safety and efficacy. The main limitations related to this system include the lack of pacing capabilities for bradycardia, tachycardia or resynchronization therapy, a large size, and relatively high energy requirements for effective defibrillation. This review article summarizes current knowledge and potential future developments of the extravascular ICD technologies.",
keywords = "Modular cardiac rhythm management system, S-ICD, Subcutaneous implantable cardioverter-defibrillator, Substernal lead, Ventricular arrhythmias",
author = "Anna Pfenniger and Knight, {Bradley Paul}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.pcad.2019.04.003",
language = "English (US)",
volume = "62",
pages = "249--255",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Evolution of extravascular implantable defibrillator technologies. / Pfenniger, Anna; Knight, Bradley Paul.

In: Progress in Cardiovascular Diseases, Vol. 62, No. 3, 01.05.2019, p. 249-255.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Evolution of extravascular implantable defibrillator technologies

AU - Pfenniger, Anna

AU - Knight, Bradley Paul

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The implantable cardioverter-defibrillator (ICD) has been successfully treating patients with lethal ventricular arrhythmias for decades. The main acute and chronic complications of this therapy modality are related to the use of a transvenous lead. An entirely extravascular ICD concept was developed over the last 20 years, with emergence of the subcutaneous ICD (S-ICD). This device was approved for clinical use seven years ago, and accumulating real-life experience confirms its safety and efficacy. The main limitations related to this system include the lack of pacing capabilities for bradycardia, tachycardia or resynchronization therapy, a large size, and relatively high energy requirements for effective defibrillation. This review article summarizes current knowledge and potential future developments of the extravascular ICD technologies.

AB - The implantable cardioverter-defibrillator (ICD) has been successfully treating patients with lethal ventricular arrhythmias for decades. The main acute and chronic complications of this therapy modality are related to the use of a transvenous lead. An entirely extravascular ICD concept was developed over the last 20 years, with emergence of the subcutaneous ICD (S-ICD). This device was approved for clinical use seven years ago, and accumulating real-life experience confirms its safety and efficacy. The main limitations related to this system include the lack of pacing capabilities for bradycardia, tachycardia or resynchronization therapy, a large size, and relatively high energy requirements for effective defibrillation. This review article summarizes current knowledge and potential future developments of the extravascular ICD technologies.

KW - Modular cardiac rhythm management system

KW - S-ICD

KW - Subcutaneous implantable cardioverter-defibrillator

KW - Substernal lead

KW - Ventricular arrhythmias

UR - http://www.scopus.com/inward/record.url?scp=85064734221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064734221&partnerID=8YFLogxK

U2 - 10.1016/j.pcad.2019.04.003

DO - 10.1016/j.pcad.2019.04.003

M3 - Review article

VL - 62

SP - 249

EP - 255

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 3

ER -